Posted on 6/5/16
Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that it has closed the previously-announced transaction with AstraZeneca for the exclusive U.S. rights to all products . . .
Posted on 6/5/16
OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an . . .
Posted on 6/5/16
Foundation Medicine and AstraZeneca Enter Strategic Collaboration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for . . .
Posted on 6/3/16
North Carolina Lupus Chapter to Hold Lupus Empowerment Seminar in Greensboro – June 15
The Lupus Foundation of America, North Carolina Chapter (LFANC) is hosting its “2016 Lupus Empowerment Workshop Series” in Greensboro on Wednesday, June 15.The workshop in Greensboro . . .
Posted on 6/3/16
Attention Merck Investors: It's Time to Start Worrying
Merck (NYSE:MRK), like many of its Big Pharma brethren, is angling to find ways to grow following an extended period of patent expirations sapping its ability . . .
Posted on 6/3/16
Why Keryx Biopharmaceuticals Shouldn't Be Up Today
What: Keryx Biopharmaceuticals (NASDAQ:KERX) is up 15% at 1:25 p.m. EDT after Seth Klarman's Baupost Group disclosed in a filing with the Securities and Exchange Commission . . .
Posted on 6/3/16
Better Buy: bluebird bio vs. Inovio Pharmaceuticals
While both bluebird bio (NASDAQ:BLUE) and Inovio Pharmaceuticals (NASDAQ:INO)started out 2016 poorly, the paths of the two biotech stocks have diverged greatly since late January. Bluebird's . . .
Posted on 6/3/16
PAREXEL Named Company of the Year for the Pharmaceuticals Industry with a Gold Stevie from the American Business Awards
BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, has been named Company of the Year – Pharmaceuticals in the 14th Annual American . . .
Posted on 6/2/16
University of Maryland Children's Hospital Launches New Reading Program for NICU Infants
University of Maryland Children’s Hospital (UMCH) and Port Discovery Children’s Museum, with funding from PNC Bank, has launched an innovative early childhood education program designed to . . .
Posted on 6/2/16
Q Biomed Reports On Current And New Potential Assets
Q BioMed Inc., a New York-based biotechnology acceleration company is pleased to report on new potential asset license/acquisition and an update on Man 01 development.The company . . .
Posted on 6/2/16
5 Billionaires Just Bought 3.3 Million Shares of Celldex Therapeutics
Clinical-stage biotech Celldex Therapeutics' (NASDAQ:CLDX) stock was clobbered during the general sell-off that affected its entire industry to start the year. Then, in early April, its . . .
Posted on 6/2/16
Clearside Biomedical Prices IPO
ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of . . .
Posted on 6/2/16
Onconova Files S-1 Registration Statement for Rights Offering to Shareholders
NEWTOWN, Pa., June 01, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to . . .
Posted on 6/2/16
Antera Raises $1.7M
Antera Therapeutics announced today that it has raised $1.7M in Series Seed financing for the launch of Aralyte™, the doctor-recommended
Posted on 6/2/16
Xenetic Biosciences Announces Reverse Stock Split
LEXINGTON, Mass.--(BUSINESS WIRE)--Xenetic Biosciences, Inc. (OTCQB: XBIO) (“Xenetic” or “the Company”), a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that . . .
Posted on 6/2/16
This Baltimore Hospital is Opening a Startup Incubator
There’s been a lot of talk about bolstering institutions like universities as places to drive the entrepreneurship Maryland needs to
Posted on 6/1/16
Reata Pharmaceuticals Closes IPO
IRVING, Texas, June 01, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced the completion of its initial public offering of 6,325,000 . . .
Posted on 6/1/16
Aldeyra Therapeutics Closes Stock Offering
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of . . .
Posted on 6/1/16
Orgenesis and CureCell Create Joint Venture for Contract Development and Manufacturing of Cell Therapy Products in South Korea
Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning . . .
Posted on 6/1/16
Maryland Ranks 41st among the US States and Puerto Rico for its Fiscal Health
On the basis of its fiscal solvency in five separate categories, Maryland ranks 41st among the US states and Puerto Rico for its fiscal health. On . . .
Posted on 6/1/16
Better Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc.
Biotech stocks haven't performed very well over the past 12 months. A couple of them have seen downright dismal results. Shareholders of Celldex Therapeutics, Inc. (NASDAQ:CLDX)have . . .
Posted on 5/19/16
A Video Conversation with John Palumbo, CEO of HealthRight - Part V
Brought to you by Newmark Grubb Knight Frank
Posted on 5/2/16
A Video Conversation with John Palumbo, CEO of HealthRight - Part IV
Brought to you by Newmark Grubb Knight Frank
Posted on 4/19/16
A Video Conversation with John Palumbo, CEO of HealthRight - Part III
Brought to you by Newmark Grubb Knight Frank
Posted on 4/11/16
A Video Conversation with John Palumbo, CEO of HealthRight - Part II
Brought to you by Newmark Grubb Knight Frank
